An evaluation of the clinical treatment effect on chronic hepatitis B optimized for HBV RNA

Abstract

Abstract: Objective To explore the effect of HBV RNA optimized therapy in the clinical treatment of chronic hepatitis B patients after HBV DNA serum disappearance, and to analyze the feasibility of this treatment by comparing with the serological markers of patients received traditional treatment. Methods A total of 118 patients with chronic hepatitis B were included in this study. They were treated with entecavir in early stage. After the patients' serum HBV DNA turned negative, the control group was continuously treated with entecavir, and the experimental group was treated with PEG-interferon α-2b. The data of serum makers in different treatment stages were collected, and the effects of different treatment methods were compared by comparing the alteration and negative conversion rates of HBsAg and HBeAg between the two groups. Results The monthly average decrease in serum HBsAg and HBeAg levels of patients in the experimental group were higher than those in the control group during each treatment period, and the decrease rates were higher than those in the control group after treatment. After 1 month of interferon treatment in the experimental group of patients, the serum HBsAg and HBeAg decreased by 191.8 IU/mL and 8.39 COI, respectively. After 3 months of treatment, the serum HBsAg and HBeAg decreased by 110.9 IU/mL and 2.61 COI, respectively, with faster rates than those of the control group (P<0.05). After 48 weeks of treatment, the HBsAg and HBeAg conversion rates in the experimental group were 14.7% and 27.8%, respectively, which were higher than those of the control group (P<0.05). Conclusion In the treatment of chronic hepatitis B, HBV RNA as well as HBV DNA are therapeutic indicators that are worthy of attention. The levels of serum HBsAg and HBeAg can be significantly reduced by treating HBV RNA when HBV DNA has turned negative, and some patients can reach the requirement of clinical cure.

Key words: Chronic hepatitis B, Hepatitis B virus RNA, Hepatitis B surface antigen, Hepatitis B e antigen, Entecavir, Pegylated interferon α-2b

PENG Min, KAN Jun-ze, GAO Hui, KAN Xiao. An evaluation of the clinical treatment effect on chronic hepatitis B optimized for HBV RNA[J]. Chinese Hepatolgy, 2025, 30(2): 170-174.

References

[1] Tang L S Y, Covert E, Wilson E, et al. Chronic Hepatitis B Infection: A Review [J]. Jama,2018,319(17):1802-1813.
[2] Su S, Wong W C, Zou Z, et al. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation [J]. Lancet Glob Health,2022,10(2):e278-e287.
[3] Tseng T C, Kao J H. Elimination of Hepatitis B: Is It a Mission Possible? [J]. BMC Med,2017,15(1):53.
[4] Wang J, Yu Y, Li G, et al. Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients [J]. J Hepatol,2017:S0168-8278(17)32261-32264.
[5] Kumar R, Pérez-del-pulgar S, Testoni B, et al. Clinical relevance of the study of hepatitis B virus covalently closed circular DNA [J]. Liver Int,2016,36 Suppl 1:72-77.
[6] Diogo Dias J, Sarica N, Neuveut C. Early Steps of Hepatitis B Life Cycle: From Capsid Nuclear Import to cccDNA Formation [J]. Viruses,2021,13(5):757.
[7] Mak L Y, Cloherty G, Wong D K, et al. HBV RNA Profiles in Patients With Chronic Hepatitis B Under Different Disease Phases and Antiviral Therapy [J]. Hepatology,2021,73(6):2167-2179.
[8] Ren H, Huang Y. Effects of pegylated interferon-α based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B [J]. J Viral Hepat,2019,26 Suppl 1:5-31.
[9] Martinez M G, Boyd A, Combe E, et al. Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections [J]. J Hepatol,2021,75(3):706-717.
[10] Xie D Y, Ren Z G, Zhou J, et al. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights [J]. Hepatobiliary Surg Nutr,2020,9(4):452-463.
[11] Hu P, Ren H. Interpretations of EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection [J]. Zhonghua Gan Zang Bing Za Zhi,2017,25(6):415-418.
[12] Revill P A, Chisari F V, Block J M, et al. A global scientific strategy to cure hepatitis B [J]. Lancet Gastroenterol Hepatol,2019,4(7):545-558.
[13] Li W J, Xu H X, Wu D S, et al. A novel fully automated system for quantification of Hepatitis B virus DNA using magnetic bead-based method combined with real-time PCR [J]. J Virol Methods,2017,248:130-135.
[14] Deng R, Liu S, Shen S, et al. Circulating HBV RNA: From biology to clinical applications [J]. Hepatology,2022,76(5):1520-1530.
[15] Liang T J, Block T M, Mcmahon B J, et al. Present and future therapies of hepatitis B: From discovery to cure [J]. Hepatology,2015,62(6):1893-1908.
[16] Lee J M, Ahn S H. Quantification of HBsAg: basic virology for clinical practice [J]. World J Gastroenterol,2011,17(3):283-289.
[17] Shen S, Xie Z, Cai D, et al. Biogenesis and molecular characteristics of serum hepatitis B virus RNA [J]. PLoS Pathog,2020,16(10):e1008945.
[18] Wang J, Shen T, Huang X, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound [J]. J Hepatol,2016,65(4):700-710.
[19] Jiang B, Dai Q, Liu Y, et al. Levels of HBV RNA in chronic HBV infected patients during first-line nucleos(t)ide analogues therapy [J]. Infect Agent Cancer,2022,17(1):61.
[20] Wang Y X, Niklasch M, Liu T, et al. Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication [J]. J Hepatol,2020,72(5):865-876.
[21] Gao B, Duan Z, Xu W, et al. Tripartite motif-containing 22 inhibits the activity of hepatitis B virus core promoter, which is dependent on nuclear-located RING domain [J]. Hepatology,2009,50(2):424-433.
[22] Gordien E, Rosmorduc O, Peltekian C, et al. Inhibition of hepatitis B virus replication by the interferon-inducible MxA protein [J]. J Virol,2001,75(6):2684-2691.
[23] Gao Y, Li Y, Meng Q, et al. Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment? [J]. J Clin Microbiol,2017,55(10):2972-2982.
[24] Terrault N A, Bzowej N H, Chang K M, et al. AASLD guidelines for treatment of chronic hepatitis B [J]. Hepatology,2016,63(1):261-283.
[25] Koumbi L. Current and future antiviral drug therapies of hepatitis B chronic infection [J]. World J Hepatol,2015,7(8):1030-1040.
[26] Bazinet M, Pântea V, Placinta G, et al. Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection NaÏve to Nucleos(t)ide Therapy [J]. Gastroenterology,2020,158(8):2180-2194.
[27] Yang Z, Sun B, Xiang J, et al. Role of epigenetic modification in interferon treatment of hepatitis B virus infection [J]. Front Immunol,2022,13:1018053.
[28] Lee H W, Lee J S, Ahn S H. Hepatitis B Virus Cure: Targets and Future Therapies [J]. Int J Mol Sci,2020,22(1):213.